

December 30, 2021

Contents

Clinical Profile Documentation.....	2
Additions	2
Updates	2
Medications	2
Additions	2
Updates	3
Regimens	3
Additions	3
Updates	3
Renames	4
Removals	4
Research	4
Additions	4
Updates	4
Billing: HCPCS & CPT Codes.....	5
HCPCS Updates	5
CPT Updates	6
Procedure Updates	7
Lab Analytes & Panels Additions.....	7

Clinical Profile Documentation

With the latest Health Language Inc. (HLI) load to the Generation 2 application SNOMED-CT terminology has been updated per SNOMED standards:

- Quality improvement tasks were deployed to improve internal structural consistency and ensure compliance with editorial policy related to the stated modeling of content.
- Correction or addition of defining relationships was carried out to accurately reflect current clinical knowledge and ensure the semantic reliability of descriptions associated with a concept.

Additions

The following items are available for documentation in **Problems** and appear on the **Charge Capture Report (CCR)**. **NOTE:** The ICD10 code choice(s)* below are not an exclusive list of codes for each problem row.

Problem	ICD-10 Code Choice(s)*
Chest pain	<ul style="list-style-type: none"> • R07.81 Pleurodynia • R07.82 Intercostal pain • R07.89 Other chest pain • R07.9 Chest pain, unspecified
Leukopenia (disorder)	<ul style="list-style-type: none"> • D72.818 Other decreased white blood cell count
Postprocedural seroma	<ul style="list-style-type: none"> • L76.34 Postprocedural seroma of skin and subcutaneous tissue following other procedure
Thromboembolism of vein	<ul style="list-style-type: none"> • I82.91 Chronic embolism and thrombosis of unspecified vein
Venous thrombosis	<ul style="list-style-type: none"> • I82.91 Chronic embolism and thrombosis of unspecified vein

Updates

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses:

- Thromboembolism of vein

Medications

Additions

- AMG 160 invest IV
- Bemarituzumab (AMG 552) invest IV
- Besremi (Ropeginterferon alfa-2b-njft Subcutaneous)
- Camrelizumab (SHR-1210) invest IV

- ERAS-007 invest Oral
- Evusheld (Tixagevimab-Cilgavimab IM Dose Pack 150 mg/1.5 mL-150 mg/1.5 mL (EUA))
- Fyarro (Sirolimus-Protein Bound IV)
- KIN-2787 invest Oral
- Mouthwash (Tacrolimus-Dexamethasone) Oral Liquid
- Ropeginterferon alfa-2b-njft Subcutaneous
- Sirolimus-Protein Bound IV
- T3011 1x10e6 pfu invest IV
- T3011 1x10e7 pfu invest IV
- T3011 1x10e8 pfu invest IV
- TH1902 invest IV
- TransCon TLR7/8 Agonist invest Intratumoral

Updates

- HepaGam B (Hepatitis B Immune Globulin-Maltose IV)
 - Added new unit: mL
- Mosunetuzumab invest Subcutaneous (BTCT4465A invest Subcutaneous)
 - Synonym is now available

Regimens

Additions

Regimen Name
Daratumumab IV + Carfilzomib D1,8,15 + Lenalidomide + Dexamethasone Q28D
Etoposide D1-4 + Ifosfamide Bolus D1-4 + Cisplatin D1-4 (VIP) Q21D (Thymoma)
Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical)
Pembrolizumab + Paclitaxel + Cisplatin + Bevacizumab Q21D (Cervical)
Pembrolizumab + Paclitaxel + Cisplatin Q21D (Cervical)
Pemetrexed + Cisplatin + Bevacizumab Q21D (Mesothelioma)
Megestrol D1-21 alternating with Tamoxifen D22-42 Q42D
Neratinib Dose Titration + Capecitabine D1-14 Q21D
Tixagevimab-Cilgavimab (Evusheld) (COVID-19 Pre-Exposure Prophylaxis)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Cervical Cancer
- Colon Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- Head and Neck Cancer (Parent)
- Lung Cancer, Non-small Cell (NSCLC)
- Malignant Mesothelioma
- Malignant Pleural Mesothelioma

- Melanoma, Skin
- Multiple Myeloma (MM)
- Ovarian and Primary Peritoneal Cancer
- Rectal Cancer
- Renal Cell Cancer (RCC)
- Uterine Cancer (Parent)

Renames

Previous Name	New Name
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin D1 + Oxaliplatin D1 (FOLFOX 6, Modified) + Panitumumab Q14D	Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Panitumumab Q14D
Pembrolizumab Q21D (Flat Dose, Adjuvant Melanoma)	Pembrolizumab Q21D (Flat Dose) (Adjuvant Melanoma, RCC)
Pembrolizumab Q42D (Flat Dose, Adjuvant Melanoma)	Pembrolizumab Q42D (Flat Dose) (Adjuvant Melanoma, RCC)
Pembrolizumab Q42D (Dose Banding, Adjuvant Melanoma)	Pembrolizumab Q42D (Dose Banding) (Adjuvant Melanoma, RCC)

Removals

- Alemtuzumab (Campath) D1,3,5 Q7D (Maintenance)
- Alemtuzumab (Campath) Q7D (Initial)

Research

Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Updates

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 16104	X	X		
USOR 17188	X	X	X	
USOR 17194	X			

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 18095		X		
USOR 18229	X	X		
USOR 19018	X	X		
USOR 19092	X			
USOR 19151	X	X	X	Now available for ordering: USOR 19151 MRTX849 + Cetuximab D1,15 Q28D
USOR 19182	X	X		
USOR 19205	X	X	X	
USOR 19236		X		
USOR 20235	X	X		
USOR 20343	X	X	X	
USOR 20409	X	X	X	Now available for ordering: USOR 20409 Arm 2 Tucatinib (PO; BID) + Cinrebausp Alfa D1,15 Q28D
USOR 20414	X	X	X	
USOR 21219		X		
USOR 21400	X			

Billing: HCPCS & CPT Codes

- Complete list of January 2022 updates: [CMS HCPCS Quarterly Updates](#)
- Complete details on [CMS HCPCS Coding Decisions](#)

HCPCS Updates

NOTIFICATION: Effective Jan 1, 2022*:

- The HCPCS code and billing dose for **Pegfilgrastim (excluding bioisimilar)** will change from J2505 per 6 mg to **J2506 per 0.5 mg** injection.

Medication	HCPCS Code
Abecma (Idecabtagene Vicleucel IV)	Q2055 per 300, 450, 460 x 10e6 CARpos viable T cells

Medication	HCPCS Code
Aduhelm (Aducanumab-avwa, IV)	J0712 per 2 mg
Available on 1/5/22 per FDB: Camcevi (Leuprolide)	J1952 per 1 mg
Evusheld (Tixagevimab IM (1 of 2) (EUA))	J3590 per 150 mg
Evusheld (Cilgavimab IM (2 of 2) (EUA))	J3590 per 150 mg
Factor IX Complex IV	J7194 per 1 unit
Factor IX Human (Recom Thr148) IV	J7195 per 1 unit
Factor IX Recomb, Fc Fusion Protein IV	J7201 per 1 unit
Fyarro (Sirolimus-Protein Bound IV)	J9999 per 100 mg
Jemperli (Dostarlimab-gxly IV)	J9272 per 10 mg
Ketamine Subcutaneous	J3490 per 10 mg
Lidocaine Intra-Articular	J2021 per <ul style="list-style-type: none"> • 0.5 mL • 1 mL
Methylene Blue IV	Q9968 per 1 mg
Neulasta (Pegfilgrastim Subcutaneous)*	J2506 per 0.5 mg
Neulasta (Pegfilgrastim Subcutaneous (via wearable injector))*	J2506 per 0.5 mg
Ropeginterferon alfa-2b-njft (Besremi) Subcutaneous	J3590 per 500 mcg
Rybrevant (Amivantamab-vmjw IV)	J9061 per 2 mg
Rylaze (Asparaginase Erwinia-rywn IM)	J9021 per 0.1 mg
Ryplazim (Plasminogen, Human-tvmh IV)	J3490 per 68.8 mg
Vosoritide Subcutaneous	J3590 per – <ul style="list-style-type: none"> • 0.4 mg • 0.56 mg • 1.2 mg

CPT Updates

For the complete list of 2022 CPT updates please see the [2022 CPT Workbook](#) document.

Summary of Total Changes – 405

- New Codes – 249
- Revised Codes – 93
- Deleted Codes – 63

Procedure Updates

Procedure mappings have been performed for the following synonyms to ensure CPT codes will display for charting and generate for charge capture report (CCR):

Procedure Description	CPT Code
Anoscopy (procedure)	46600
Endometrial biopsy	58100, 58110, 58558
Punch biopsy of skin lesion (procedure)	11104
Punch biopsy of skin lesion (procedure)	11105

Lab Analytes & Panels Additions

<ul style="list-style-type: none"> • A diagnosis, tissue pathology • A gross description, tissue pathology • A procedure, tissue pathology • B diagnosis, tissue pathology • B gross description, tissue pathology • B procedure, tissue pathology • B2 glycoprotein I ab, IgA, U/mL • C. diff Toxin/GDH comment • C. diff Toxin/GDH micro number • C. diff Toxin/GDH report status • C. diff Toxin/GDH source • C. diff Toxin/GDH specimen quality • C. diff Toxin/GDH w/Reflex to PCR panel • C. difficile glutamate dehydrogenase antigen • C. difficile toxins A + B • Calc triglyceride/HDL • Chlamydia trachomatis, NAA • CMV Ab, IgG, AI • CMV ab, IgG, U/mL • CMV Ab, IgM result • CMV Ab, IgM, AI • CMV ab, IgM, AU/mL • CSF histiocyte, % • Cytomegalovirus IgM, IgG panel • Fentanyl confirmation, blood • Gabapentin confirmation, blood • Hepatitis B core antibody, total • Hepatitis B immunity interpretation • Hepatitis B profile X (immunity status) panel • Hepatitis B profile X reflex to HBC IgM 	<ul style="list-style-type: none"> • Hepatitis B surface ab, qual • Hepatitis B surface antigen screen • HIV-1 DNA, qual RT PCR • HIV-1 DNA, qual RT PCR panel • HSV 1 IgG result • HSV 1 NAA • HSV 1 specific Ab, IgG • HSV 2 NAA • Immunotyping urine comment • Iron panel (FE, TIBC) • Iron profile (FE, TIBC, Ferritin) • Lymph2Cx test • Lymph3Cx test • Neisseria gonorrhoeae, NAA • NuSwab STD - Ct Ng TV HSV panel, NAA • Pleximark (TM) panel • S. rectivirgula Ab, qual • SM ab, EU • SM/RNP ab, EU • Soluble IL-2R panel • Soluble IL2R • Soluble IL-2R assay description • Tissue pathology panel • Tissue pathology, clinical Information • Tissue pathology, pathologist • Tissue pathology, report notes • Trichomonas vaginalis, NAA • Yo Ab screen w/ Reflex to titer and western blot • Yo Ab, western blot, serum
---	---